Chloroquine and its cousin hydroxychloroquine may end up being a highly effective treatment for COVID-19, but patients who try out the suddenly popular anti-malaria drug have plenty to lose, despite what President Trump says. Doctors and researchers around the world have identified promising examples of hydroxychloroquine helping COVID-19 patients-and since there are still no approved treatments for the disease and no vaccine, some doctors view it as the best option. This was in addition to drugs administered per hospital protocol, including the antibiotic drug azithromycin. By the sixth day of treatment, 11 patients had died, leading to an immediate end to the high-dose segment of the trial.
President Trump tweeted that "HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine" after anecdotal information suggested they may improve coronavirus patients' prospects. "However, decision is yet to be made in this regard", the ministry sources said.
"At this level, the drug isn't beneficial for use by means of sufferers apart from by means of clinical execs prescribing it as a part of ongoing investigational research", a Central Intelligence Agency web page for staff learn in overdue March.
"Health authorities worldwide have recommended hydroxychloroquine for COVID-19 patients with positive outcomes".
Call of Duty Warzone Passes 50 Million Players
This is exceeding all expectations considering that the game is only one month old (being released on March 10). This is how to use quips in Call of Duty: Modern Warfare .
"Use of chloroquine or hydroxychloroquine to prevent coronavirus infection is disqualifying while on the medication and for 48 hours after the last dose before reporting for flight or other safety related duties", the directive from the director of the Medical Specialties Division Dr.
The researchers said the study did not have enough patients in the lower-dose portion of the trial to conclude if chloroquine was effective in patients with severe disease.
During the study, half of the patients were given the standard dose of 450 milligrams of chloroquine two times a day for five days, and the others were given a higher dose of 600 milligrams over 10 days. The New York Post reports that the scientists said: "the trend towards higher fatality associated with the higher dose by day 6 of follow-up resulted in a premature halting" of giving higher doses to patients. Eleven patients died after six days, but no reports show whether it was due to the drug or the virus itself.
In recent weeks, pharmaceutical companies such as Novartis and Rising Pharmaceuticals have supported clinical trials exploring HCQ as a treatment for COVID-19, adding that they have donated more than 200,000 doses of HCQ to the University of Washington for a COVID-19 PEP clinical trial.
"That is the reason this arm of the study was halted early", he said, adding that the manuscript was being reviewed by the journal Lancet Global Health.